AbbVie Q2 Skyrizi Revenue Forecast | Polymarket Trade

AbbVie's Skyrizi (risankizumab), a psoriasis and Crohn's disease treatment, represents one of the company's key revenue drivers. The second-quarter earnings period provides a critical window into the drug's market adoption and commercial performance. These four prediction markets track AbbVie's reported Q2 global Skyrizi net revenues across a range of thresholds—$18 billion, $19 billion, $20 billion, and $21 billion—allowing market participants to forecast where the actual result will fall. The clustering of these markets at $1 billion intervals creates a natural ladder effect: as you move from the lowest threshold to the highest, the probability of each outcome shifts based on collective expectations about Skyrizi's commercial trajectory. This structure helps identify consensus views on revenue performance. If the market assigns high probability to the $19B threshold but lower probability to $18B, it suggests participants expect growth above that level. Conversely, if $21B markets show very low probability, it reflects skepticism about the drug reaching the highest revenue ceiling. When reading the prices below, look for implicit probability spreads between adjacent thresholds. A tight spread might indicate genuine uncertainty at that particular revenue band; a wider gap could signal stronger conviction about exceeding or falling short of a specific level. You should also consider Skyrizi's historical growth trajectory, recent clinical data, competitive pressures in immunology markets, and any forward guidance from AbbVie management. These macroeconomic factors—alongside supply-chain dynamics and international pricing variations—shape the underlying probabilities reflected in the prediction markets. Market prices update continuously as new information emerges, so comparing these four outcomes gives you a sophisticated lens through which to evaluate AbbVie's upcoming earnings report.